News
-
-
-
PRESS RELEASE
Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program
Newron Pharmaceuticals provides update on FDA Clinical Hold and Phase 3 ENIGMA-TRS development program, reviewing feedback and preparing response. ENIGMA-TRS 1 enrollment completion by mid-October, 12-week data expected Q1 2027 -
-
-
-
-
-
PRESS RELEASE
Newron reports subscription for EUR 5.5 million of shares by investor group as part of up to EUR 38 million total financing to advance Phase 3 evenamide program
Newron Pharmaceuticals S.p.A. secures EUR 5.5 million from investor group to advance Phase 3 evenamide program, with total financing of up to EUR 38 million -
